Swift Biosciences nets $7 mln in Series B financing
Swift Biosciences has closed $7 million in Series B financing. Fletcher Spaght Ventures led the round with participation from Renaissance Venture Capital Fund, the Mercury Fund, Michigan Accelerator Fund and several Michigan-based individual investors. In conjunction with the funding, the company has named Peter Kleinhenz, a partner at Fletcher Spaght Ventures, to its board of directors. Based in Ann Arbor, Michigan, Swift Biosciences develops technologies for genomics and personalized medicine.
18 October 2013•3 mins read
